Could a common ED drug shield newborn brains? 24-Baby trial launches

NCT ID NCT06810284

First seen Feb 20, 2026 · Last updated Apr 29, 2026 · Updated 8 times

Summary

This study tests whether adding the drug sildenafil to standard cooling treatment can help prevent brain damage in full-term newborns who suffered oxygen loss at birth. About 24 babies will receive IV sildenafil while being cooled, and researchers will measure how the drug behaves in their bodies. The goal is to prepare for a larger trial that could show if this combination improves survival without brain injury.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOXIC-ISCHEMIC ENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Unité de Recherche Clinique, Entrepôts de données et Pharmacologie GHU Paris Centre

    Paris, 75005, France

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.